Opicinumab

Drug Profile

Opicinumab

Alternative Names: Anti-LINGO-1; Anti-LINGO-1 antibody; BIIB-033

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Biogen Idec; Dyax
  • Developer Biogen
  • Class Antibodies; Monoclonal antibodies; Neuropsychotherapeutics
  • Mechanism of Action Cell differentiation stimulants; LINGO-1-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis; Optic neuritis

Most Recent Events

  • 01 Jan 2017 Biogen completes the follow-up RENEWed trial for Optic neuritis in United Kingdom, Germany, Hungary, Sweden, Spain, Belgium, Czech Republic, Italy, Denmark, Canada and Australia (NCT02657915)
  • 01 Nov 2016 Biogen completes a phase I pharmacokinetics trial in Healthy volunteers in USA (IV) (NCT02833142)
  • 01 Sep 2016 Biogen initiates a phase I trial in Healthy volunteers in United Kingdom (IV) (NCT02641041)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top